יתרות המזומנים של החברה: gaintherapeutics.com (GANX)

Gain Therapeutics, Inc. (GANX) develops cutting-edge treatments to combat genetic and neurodegenerative pathologies. The size of the cash reserve demonstrates financial stability, where 0.01 forms the current metric value. Stable demand for healthcare protects the business from market downturns, although the lack of profitability and early-stage testing create a need for continuous venture capital.
פילוחי נתונים אנליטיים מרוכזים עבור Gain Therapeutics, Inc. (GANX)

This indicator captures the organization's actual liquidity, allowing for an assessment of the capital burn rate and the risk of a cash crunch regardless of management's declarations. By analyzing the size of the cash reserve, an investor can determine the ability of Gain Therapeutics, Inc. (GANX) to maintain costly scientific alliances and joint drug development for rare diseases without the urgent need for external financing.